Chanhyun Park1, Sun-Kyeong Park2, Ahye Woo3, Boon Peng Ng4,5. 1. Health Outcome Division, The University of Texas at Austin College of Pharmacy, 2409 University Avenue MC A1930, Austin, TX, 78712-1120, USA. chanhyun.park@austin.utexas.edu. 2. School of Pharmacy, The Catholic University of Korea, Bucheon, South Korea. 3. Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA. 4. College of Nursing, University of Central Florida, Orlando, FL, USA. 5. Disability, Aging, and Technology Cluster, University of Central Florida, Orlando, FL, USA.
Abstract
OBJECTIVES: The evidence regarding the impact of individual adjuvant endocrine therapies (AET) on health-related quality of life (HRQoL) is limited. We aimed to assess the association between the type of AET and HRQoL and to examine the relationship between HRQoL and one-year mortality among women with breast cancer in the USA. METHODS: This retrospective cross-sectional study used the 2006-2017 Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey database to identify older women with early-stage hormone receptor-positive breast cancer. Multivariate linear regressions were used to assess the association between types of AET (anastrozole, letrozole, exemestane, and tamoxifen) and HRQoL scores (physical component summary (PCS) and mental component summary (MCS)). Multivariate logistic regressions were used to predict the impact of PCS and MCS on one-year mortality. RESULTS: Out of 3537 older women with breast cancer, anastrozole was the most commonly prescribed (n = 1945, 55.0%). Regarding PCS, there was no significant difference between the four AET agents. Higher MCS scores, which indicate better HRQoL, were reported in patients treated with anastrozole (vs. letrozole [β = 1.26, p = 0.007] and exemestane [β = 2.62, p = 0.005) and tamoxifen (vs. letrozole [β = 1.49, p = 0.010] and exemestane [β = 2.85, p = 0.004]). Lower PCS and MCS scores were associated with higher one-year mortality, regardless of type of AET initiated, except for tamoxifen in MCS. CONCLUSION: Although there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores.
OBJECTIVES: The evidence regarding the impact of individual adjuvant endocrine therapies (AET) on health-related quality of life (HRQoL) is limited. We aimed to assess the association between the type of AET and HRQoL and to examine the relationship between HRQoL and one-year mortality among women with breast cancer in the USA. METHODS: This retrospective cross-sectional study used the 2006-2017 Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey database to identify older women with early-stage hormone receptor-positive breast cancer. Multivariate linear regressions were used to assess the association between types of AET (anastrozole, letrozole, exemestane, and tamoxifen) and HRQoL scores (physical component summary (PCS) and mental component summary (MCS)). Multivariate logistic regressions were used to predict the impact of PCS and MCS on one-year mortality. RESULTS: Out of 3537 older women with breast cancer, anastrozole was the most commonly prescribed (n = 1945, 55.0%). Regarding PCS, there was no significant difference between the four AET agents. Higher MCS scores, which indicate better HRQoL, were reported in patients treated with anastrozole (vs. letrozole [β = 1.26, p = 0.007] and exemestane [β = 2.62, p = 0.005) and tamoxifen (vs. letrozole [β = 1.49, p = 0.010] and exemestane [β = 2.85, p = 0.004]). Lower PCS and MCS scores were associated with higher one-year mortality, regardless of type of AET initiated, except for tamoxifen in MCS. CONCLUSION: Although there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores.
Authors: F Efficace; L Biganzoli; M Piccart; C Coens; K Van Steen; T Cufer; R E Coleman; H A Calvert; T Gamucci; C Twelves; P Fargeot; A Bottomley Journal: Eur J Cancer Date: 2004-05 Impact factor: 9.162
Authors: F Cardoso; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; I T Rubio; S Zackrisson; E Senkus Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Harold J Burstein; Sarah Temin; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Diana Rowden; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2014-05-27 Impact factor: 44.544
Authors: Ian Smith; Denise Yardley; Howard Burris; Richard De Boer; Dino Amadori; Kristi McIntyre; Bent Ejlertsen; Michael Gnant; Walter Jonat; Kathleen I Pritchard; Mitch Dowsett; Lowell Hart; Susan Poggio; Lisa Comarella; Herve Salomon; Barbara Wamil; Joyce O'Shaughnessy Journal: J Clin Oncol Date: 2017-01-23 Impact factor: 44.544
Authors: Rebeca Stahlschmidt; Amanda Canato Ferracini; Cinthia Madeira de Souza; Luana Moreira de Medeiros; Cassia Raquel Teatin Juliato; Priscila Gava Mazzola Journal: Support Care Cancer Date: 2019-02-06 Impact factor: 3.603
Authors: Paul E Goss; James N Ingle; Kathleen I Pritchard; Matthew J Ellis; George W Sledge; G Thomas Budd; Manuela Rabaglio; Rafat H Ansari; David B Johnson; Richard Tozer; David P D'Souza; Haji Chalchal; Silvana Spadafora; Vered Stearns; Edith A Perez; Pedro E R Liedke; Istvan Lang; Catherine Elliott; Karen A Gelmon; Judy-Anne W Chapman; Lois E Shepherd Journal: J Clin Oncol Date: 2013-01-28 Impact factor: 44.544